Jesang Ko

Dr. Jesang Ko

Korea University, Division of Life Sciences, 5-1 Anam-dong, Seongbuk-gu, Seoul 136–701, Korea
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Cellular Physiology and Biochemistry
Verified
Journal Article
Closed access
PDF file
YKYoonseo Kim
Yoonseo Kim
HKHyereen Kang
Hyereen Kang
SJSung-Wuk Jang
Sung-Wuk Jang
Jesang KoJesang Ko
Jesang Ko
Background/Aims: Metastasis is one of the main causes of death for patients with malignant tumors. Induction of matrix metalloproteinase (MMP)-9 is particularly important for the invasiveness of various cancer cells. Celastrol, a triterpenoid isolated from the traditional Chinese medicine, is known to inhibit the proliferation of a variety of tumor cells, including leukemia, glioma, prostate and breast cancer cells. In this study, we investigated the effect of celastrol on the migration and invasion of human breast carcinoma cells. Results: We observed that celastrol suppressed phorbol 12-myristate 13-acetate (PMA)-induced invasion and migration of MCF-7 cells. We also found that celastrol inhibited PMA-induced MMP-9 expression at both the mRNA and the protein levels, and the proteolytic activity of MMP-9 in MCF-7 cells. Our results revealed that celastrol inhibited the transcriptional activity of MMP-9 by suppression of the DNA binding activity of NF-ĸB in the MMP-9 promoter, and inhibited degradation of IĸBα and nuclear translocation of NF-ĸB. Conclusion: These results indicate that celastrol inhibits NF-ĸB-mediated MMP-9 expression, resulting in suppression of breast cancer cell invasion and migration that is induced by PMA. Celastrol is a potential agent for clinical use in preventing the invasion and metastasis of human malignant breast tumors.

1 July 2014 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
JKJeonghan Kim
Jeonghan Kim
SJSung-Wuk Jang
Sung-Wuk Jang
EPEunsoo Park
Eunsoo Park
MOMinseok Oh
Minseok Oh
SPSodam Park
Sodam Park
Jesang KoJesang Ko
Jesang Ko

6 December 2018 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MKMinsoo Kang
Minsoo Kang
SKSuhyun Kim
Suhyun Kim
Jesang KoJesang Ko
Jesang Ko
Extracellular vesicles contain various cellular components that are involved in tumor growth, metastasis, and immune escape. Extracellular vesicles are classified into 2 groups, namely, exosomes and microvesicles (MV). Although the formation and roles of exosomes have been studied, the exact functions of MVs and mechanisms underlying MV release are not fully understood. We found that epidermal growth factor accelerates the release of MVs from the plasma membrane by inducing NF‐κB activation and CD133 expression. The amount and sizes of budding MVs were found to be dependent on the expression level of CD133, which regulates the activities of the small guanosine 5′‐triphosphatases RhoA and Rac1. CD133‐containing MVs released from KRAS mutant colon cancer cells delivered KRAS mutant to adjacent nontumorigenic cells and activated KRAS downstream signaling. CD133‐containing MVs were found to promote the migration and invasion of adjacent cells. CD133‐containing MVs induced the development of chemoresistance by abolishing the inhibitory effects of anti‐epidermal growth factor receptor (EGFR) drugs on cell proliferation and motility in colon cancer. These results suggest that CD133 acts as a novel modulator in MV release and in oncoprotein trafficking. CD133 can serve as a therapeutic target for treatment of anti‐EGFR drug‐resistant colon cancer.—Kang, M., Kim, S., Ko, J. Roles of CD133 in microvesicle formation and oncoprotein trafficking in colon cancer. FASEB J. 33, 4248–4260 (2019). www.fasebj.org

1 December 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HKHyereen Kang
Hyereen Kang
SJSung-Wuk Jang
Sung-Wuk Jang
Jesang KoJesang Ko
Jesang Ko
Extracellular proteolysis mediates tissue homeostasis. In cancer, altered proteolysis leads to abnormal tumor growth, inflammation, tissue invasion, and metastasis. Matrix metalloproteinase-9 (MMP-9) represents one of the most prominent proteinases associated with inflammation and tumorigenesis. The recently identified human transcription factor sLZIP is a member of the leucine zipper transcription factor family. Although sLZIP is known to function in ligand-induced transactivation of the glucocorticoid receptor, its exact functions and target genes are not known. In this study, we investigated the role of sLZIP in MMP-9 expression and its involvement in cervical cancer development. Our results show that sLZIP increased the expression of MMP-9 at both the mRNA and protein levels and the proteolytic activity of MMP-9 in HeLa and SiHa cells. sLZIP also increased the transcriptional activity of MMP-9 by binding directly to the cAMP-responsive element of the MMP-9 promoter region. Involvement of sLZIP in MMP-9 expression was further supported by the fact that ME-180 cells expressing sLZIP siRNA were refractory to MMP-9 expression. Results from wound healing and invasion assays showed that sLZIP enhanced both the migration and invasion of cervical cancer cells. The increased migration and invasion of HeLa and SiHa cells that were induced by sLZIP were abrogated by inhibition of the proteolytic activity of MMP-9. These results indicate that sLZIP plays a critical role in MMP-9 expression and is probably involved in invasion and metastasis of cervical cancer.

17 June 2011 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
HSHo Joong Sung
Ho Joong Sung
JKJeonghan Kim
Jeonghan Kim
YKYoonseo Kim
Yoonseo Kim
SJSung-Wuk Jang
Sung-Wuk Jang
Jesang KoJesang Ko
Jesang Ko

30 July 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JKJeonghan Kim
Jeonghan Kim
Jesang KoJesang Ko
Jesang Ko
Atherosclerosis is a chronic inflammatory response of the vascular wall, and immune responses are involved in every phase of atherosclerosis, from initiation, to progression, and finally to plaque rupture. Cytokines are the major atherogenic mediators that promote plaque formation and progression by activation of inflammatory cells. They induce expressions of matrix metalloproteinases (MMPs), leading to vascular smooth muscle cell (VSMC) migration in atherosclerotic lesions. Although chronic inflammatory mediators, including tumor necrosis factor α (TNF‐α) and MMPs, exacerbate atherosclerosis, the molecular mechanism of atherogenesis remains unclear. In this study we investigated the role of a novel transcription factor the human small leucine zipper protein (sLZIP) in TNF‐α‐induced MMP expression, VSMC migration, and atherosclerosis progression. The proinflammatory cytokine TNF‐α enhanced sLZIP expression by 3‐fold via activation of NF‐κB signaling. sLZIP induced MMP‐9 transcription and the proteolytic activity of MMP‐9 by 2.8‐ and 3.2‐fold ( P < 0.05), respectively, in macrophages, leading to enhancement of VSMC migration by 2.7‐fold ( P <0.005). sLZIP OE/+ (sLZIP transgenic); LDLR ‐/‐ mice fed a high‐cholesterol diet exhibited enhanced arterial plaque formation and increased VSMC migration from the media into the intima by 2.8‐ and 2.6‐fold ( P <0.01), respectively, compared with atherosclerosis‐prone LDLR ‐/‐ mice. These results indicate that human sLZIP plays a critical role in development of atherosclerosis and can be used as a therapeutic target molecule for treatment of atherosclerosis.—Kim, J., Ko, J., Human sLZIP promotes atherosclerosis via MMP‐9 transcription and vascular smooth muscle cell migration. FASEB J. 28, 5010–5021 (2014). www.fasebj.org